Evidence map›Paper›PMID 35898656›Full record

ArticleStem cells international2022

Small Extracellular Vesicles from Inflamed Adipose Derived Stromal Cells Enhance the NF-

Carola Cavallo, Giulia Merli, Nicoletta Zini, Stefania D'Adamo, Luca Cattini, Michele Guescini, Brunella Grigolo, Alessandro Di Martino, Spartaco Santi, Rosa Maria Borzì and 1 more

Open access · goldAbstract read
In one paragraph

Article in Stem cells international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Engineered Extracellular Vesicles in Arthritic Diseases: Therapeutic Applications & Challenges.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Carola CavalloLaboratorio RAMSES, IRCCS Istituto Ortopedico Rizzoli, Bologna 40136, Italy.ORCID https://orcid.org/0000-0002-2913-856X
Giulia MerliApplied and Translational Research Center (ATRc), IRCCS Istituto Ortopedico Rizzoli, Bologna 40136, Italy.ORCID https://orcid.org/0000-0001-7895-5606
Nicoletta ZiniCNR Institute of Molecular Genetics "Luigi Luca Cavalli-Sforza", Unit of Bologna, Bologna 40136, Italy.ORCID https://orcid.org/0000-0002-4442-7079
Stefania D'AdamoDepartment of Medical and Surgical Sciences, University of Bologna, Bologna 40138, Italy.ORCID https://orcid.org/0000-0002-2209-9158
Luca CattiniLaboratorio di Immunoreumatologia e Rigenerazione Tissutale, IRCCS Istituto Ortopedico Rizzoli, Bologna 40136, Italy.ORCID https://orcid.org/0000-0002-9239-8110
Michele GuesciniDepartment of Biomolecular Science, University of Urbino Carlo Bo, Urbino 61029, Italy.ORCID https://orcid.org/0000-0001-9372-7038
Brunella GrigoloLaboratorio RAMSES, IRCCS Istituto Ortopedico Rizzoli, Bologna 40136, Italy.ORCID https://orcid.org/0000-0002-3990-6745
Alessandro Di MartinoClinica Ortopedica e Traumatologica 2, IRCCS Istituto Ortopedico Rizzoli, Bologna 40136, Italy.ORCID https://orcid.org/0000-0002-2411-7508
Spartaco SantiCNR Institute of Molecular Genetics "Luigi Luca Cavalli-Sforza", Unit of Bologna, Bologna 40136, Italy.ORCID https://orcid.org/0000-0001-9856-7053
Rosa Maria BorzìLaboratorio di Immunoreumatologia e Rigenerazione Tissutale, IRCCS Istituto Ortopedico Rizzoli, Bologna 40136, Italy.ORCID https://orcid.org/0000-0003-4133-4894
Giuseppe FilardoApplied and Translational Research Center (ATRc), IRCCS Istituto Ortopedico Rizzoli, Bologna 40136, Italy.ORCID https://orcid.org/0000-0002-8136-0977
Istituto Ortopedico Rizzoli · ITUniversity of Urbino · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The last decade has seen exponentially growing efforts to exploit the effects of adipose derived stromal cells (ADSC) in the treatment of a wide range of chronic degenerative diseases, including osteoarthritis (OA), the most prevalent joint disorder. In the perspective of developing a cell-free advanced therapy medicinal product, a focus has been recently addressed to the ADSC secretome that lends itself to an allogeneic use and can be further dissected for the selective purification of small extracellular vesicles (sEVs). sEVs can act as "biological drug carriers" to transfer information that mirror the pathophysiology of the providing cells. This is important in the clinical perspective where many OA patients are also affected by the metabolic syndrome (MetS). ADSC from MetS OA patients are dysfunctional and "inflammatory" primed within the adipose tissue. To mimic this condition, we exposed ADSC to IL-1

Identifiers

PMID35898656
PMCPMC9314187
OpenAlexW4285802452

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.